European Research Infrastructures for Poverty Related Diseases (EURIPRED)

NIBSC is the coordinator of EURIPRED, a collaborative programme which aims to develop an infrastructure to centralise European resources for the development of new tools (vaccines, drugs, microbicides) to combat:

• tuberculosis
• HIV
• malaria
• hepatitis B
• hepatitis C

EURIPRED is a 4-year project co-funded with €8.5 million by the European Commission and involves 17 partners from both the public and the private sectors in 11 different countries.

Through EURIPRED, new clinical isolates are currently being collected at Biobanks in Spain, Russia, UK, Kenya and China, that will be used to generate recombinant proteins, peptide sets and antibodies in all 5 disease areas.

As well as allowing easier standardisation between collaborative studies, we believe that these new reagents will be pivotal in developing new approaches to support the prevention and treatment of these poverty-related diseases. EURIPRED reagents will be distributed free of charge by the Centre for AIDS Reagents (CFAR) over the course of the project. Applications will be managed through EURIPRED Trans National Access.

Several training courses and a vaccine formulation service are also available through EURIPRED by applying to Trans National Access.

See the EURIPRED website.